keyword
https://read.qxmd.com/read/38518529/alpelisib-for-pik3ca-mutated-advanced-gynecological-cancers-first-clues-of-clinical-activity
#21
JOURNAL ARTICLE
Anna Passarelli, Vittoria Carbone, Sandro Pignata, Roberta Mazzeo, Domenica Lorusso, Giovanni Scambia, Stefania Canova, Teresa Di Palma, Giulia Tasca, Mara Mantiero, Emanuele Naglieri, Claudia Andreetta, Martina Rauso, Anna Elisabetta Brunetti, Letizia Laera, Chiara Abeni, Giuseppa Scandurra, Anna Rita Gambaro, Alessia Pastore, Carmelo Bengala, Marco Gunnellini, Alberto Farolfi, Maurizio Spinello, Michele Bartoletti
OBJECTIVE: Recurrent gynecological tumors (e.g., endometrial, and ovarian cancers) are incurable diseases; therefore, new treatment options are urgently needed. The PTEN-AKT-PI3K pathway is frequently altered in these tumors, representing a potential treatment target. Alpelisib is an α-specific PI3K inhibitor approved in PIK3CA-mutated advanced breast cancer. We report outcomes from a large series of patients with PIK3CA-mutated gynecological cancers prospectively treated with alpelisib within a controlled program...
March 21, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38517321/peritumoral-mri-radiomics-features-increase-the-evaluation-efficiency-for-response-to-chemotherapy-in-patients-with-epithelial-ovarian-cancer
#22
JOURNAL ARTICLE
Yong'ai Li, Junming Jian, Huijie Ge, Xin Gao, Jinwei Qiang
BACKGROUND: It remains unclear whether extracting peritumoral volume (PTV) radiomics features are useful tools for evaluating response to chemotherapy of epithelial ovarian cancer (EOC). PURPOSE: To evaluate MRI radiomics signatures (RS) capturing subtle changes of PTV and their added evaluation performance to whole tumor volume (WTV) for response to chemotherapy in patients with EOC. STUDY TYPE: Retrospective. POPULATION: 219 patients aged from 15 to 79 years were enrolled...
March 22, 2024: Journal of Magnetic Resonance Imaging: JMRI
https://read.qxmd.com/read/38515713/exploring-prognostic-microbiota-markers-in-patients-with-endometrial-carcinoma-intratumoral-insights
#23
JOURNAL ARTICLE
Jie Liu, Yi Qu, Yang-Yang Li, Ya-Lan Xu, Yi-Fang Yan, Hao Qin
Endometrial cancer, a leading gynecological malignancy, is profoundly influenced by the uterine microbiota, a key factor in disease prognosis and treatment. Our study underscores the distinct microbial compositions in endometrial cancer compared to adjacent non-cancerous tissues, revealing a dominant presence of p_ Actinobacteria in cancerous tissues as opposed to p_ Firmicutes in surrounding areas. Through comprehensive analysis, we identified 485 unique microorganisms in cancer tissues, 26 of which correlate with patient prognosis...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38514510/mechanism-of-regulation-of-kif23-on-endometrial-cancer-cell-growth-and-apoptosis
#24
JOURNAL ARTICLE
Ruiying Zhuang, Haiyan Liu
OBJECTIVE: The global incidence of endometrial cancer, a malignant tumor in females, is on the rise. It is one of the most common gynecological cancers. Early-stage endometrial cancers can often be treated successfully with uterine extirpation. However, those diagnosed at a later stage have a poor prognosis and encounter treatment challenges. Therefore, additional research is necessary to develop primary prevention strategies for high-risk women and improve survival rates among patients with endometrial cancer...
March 21, 2024: Discover. Oncology
https://read.qxmd.com/read/38514100/incidence-of-sentinel-lymph-node-metastases-in-apparent-early-stage-endometrial-cancer-a-multicenter-observational-study
#25
JOURNAL ARTICLE
Luigi Antonio De Vitis, Diletta Fumagalli, Gabriella Schivardi, Ilaria Capasso, Leah Grcevich, Francesco Multinu, Giuseppe Cucinella, Tommaso Occhiali, Ilaria Betella, Benedetto E Guillot, Giulia Pappalettera, Maryam Shahi, Angela J Fought, Michaela McGree, Evelyn Reynolds, Nicoletta Colombo, Vanna Zanagnolo, Giovanni Aletti, Carrie Langstraat, Andrea Mariani, Gretchen Glaser
OBJECTIVE: Ultrastaging is accurate in detecting nodal metastases, but increases costs and may not be necessary in certain low-risk subgroups. In this study we examined the risk of nodal involvement detected by sentinel lymph node (SLN) biopsy in a large population of apparent early-stage endometrial cancer and stratified by histopathologic characteristics. Furthermore, we aimed to identify a subgroup in which ultrastaging may be omitted. METHODS: We retrospectively included patients who underwent SLN (with bilateral mapping and no empty nodal packets on final pathology) ± systematic lymphadenectomy for apparent early-stage endometrial cancer at two referral cancer centers...
March 21, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38513238/diagnosis-shift-in-site-of-origin-of-tubo-ovarian-carcinoma
#26
JOURNAL ARTICLE
Matthew W Lee, Zachary S Anderson, Alodia M Girma, Maximilian Klar, Lynda D Roman, Joseph W Carlson, Jason D Wright, Anil K Sood, Koji Matsuo
OBJECTIVE: To assess population-level trends, characteristics, and outcomes of high-grade serous tubo-ovarian carcinoma in the United States. METHODS: This retrospective cohort study queried the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. The study population was 27,811 patients diagnosed with high-grade serous tubo-ovarian carcinoma from 2004 to 2020. The exposure was the primary cancer site (ovary or fallopian tube). Main outcome measures were temporal trends, clinical characteristics, and overall survival associated with primary cancer site assessed in multivariable analysis...
March 21, 2024: Obstetrics and Gynecology
https://read.qxmd.com/read/38512100/the-malignant-potential-of-ovarian-steroid-cell-tumors-revisited-a-multi-institutional-clinicopathologic-analysis-of-115-cases
#27
JOURNAL ARTICLE
Oluwole Fadare, Elmira Vaziri Fard, Rohit Bhargava, Mohamed Mokhtar Desouki, Krisztina Z Hanley, Philip P C Ip, Joshua J X Li, Bingjian Lu, Fabiola Medeiros, Joshua Hoi Yan Ng, Vinita Parkash, Andre Pinto, Charles M Quick, Stephanie L Skala, Minami Tokuyama, Gulisa Turashvili, Christina H Wei, Deyin Xing, Wenxin Zheng, T Rinda Soong, Brooke E Howitt
Steroid cell tumors (SCTs) of the ovary are rare and understudied, and as such, uncertainties remain about their malignant potential, as well as clinicopathologic predictors of patient outcome. Based on a multi-institutional cohort of cases, we present findings from the largest study of SCT reported to date. Clinicopathologic data were documented on 115 cases of SCT that were assembled from 17 institutions. The median patient age was 55 years (range: 9 to 84). When measured, preoperative androgen levels were elevated in 84...
March 21, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38509492/clinical-characteristics-and-radiation-therapy-modality-of-younger-patients-with-early-stage-endometrial-cancer-a-multicenter-study-in-china-s-real-world
#28
JOURNAL ARTICLE
Kun Zhang, Tiejun Wang, Zi Liu, Jianli He, Xiaoge Sun, Wei Zhong, Fengjv Zhao, Xiaomei Li, Sha Li, Hong Zhu, Zhanshu Ma, Ke Hu, Fuquan Zhang, Xiaorong Hou, Lichun Wei, Lijuan Zou
BACKGROUND: Endometrial cancer is a prevalent gynecologic malignancy found in postmenopausal women. However, in the last two decades, the incidence of early-stage has doubled in women under 40 years old. This study aimed to investigate the clinical and pathological characteristics and adjuvant therapeutic modalities of both young and not -young patients with early-stage endometrial cancer in China's real world. METHODS: This retrospective study analyzed patients with early-stage endometrial cancer at 13 medical institutions in China from 1999 to 2015...
March 20, 2024: BMC Cancer
https://read.qxmd.com/read/38508588/analysis-of-risk-factors-for-post-operative-recurrence-or-progression-of-intravenous-leiomyomatosis
#29
JOURNAL ARTICLE
Guorui Zhang, Xin Yu, Jinghe Lang, Bao Liu, Dachun Zhao
OBJECTIVE: To analyse the risk factors for post-operative recurrence or progression of intravenous leiomyomatosis and explore the impact of different treatment strategies on patient prognosis. METHODS: Patients with intravenous leiomyomatosis who underwent surgery from January 2011 to December 2020 and who were followed for ≥3 months were included. The primary endpoint was recurrence (for patients with complete resection) or progression (for patients with incomplete resection)...
March 19, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38508587/molecular-and-pathologic-data-to-guide-selection-of-patients-with-endometrioid-endometrial-cancer-for-ovarian-preservation
#30
JOURNAL ARTICLE
Beryl L Manning-Geist, Eric Rios-Doria, Ying L Liu, Lora H Ellenson, Qin C Zhou, Alexia Iasonos, Mario M Leitao, Nadeem R Abu-Rustum, Britta Weigelt, Jennifer J Mueller
OBJECTIVES: To investigate the association of molecular and pathologic factors with concurrent or recurrent ovarian disease to guide ovarian preservation in endometrioid endometrial cancer. METHODS: Patients with endometrial cancer ≤50 years of age at diagnosis were grouped by elective oophorectomy versus ovarian preservation at staging (January 2010 to June 2021). Tumors were stratified by molecular sub-type and CTNNB1 mutational status with next generation sequencing and immunohistochemistry...
March 19, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38508586/prognostic-role-of-transcription-factor-arid1a-in-patients-with-endometrial-cancer-of-no-specific-molecular-profile-nsmp-subtype
#31
JOURNAL ARTICLE
Arina Onoprienko, Gerda Hofstetter, Leonhard Muellauer, Tim Dorittke, Stephan Polterauer, Christoph Grimm, Thomas Bartl
OBJECTIVE: As more than 50% of newly diagnosed endometrial cancers remain classified as 'no specific molecular subtype' (NSMP) due to a lack of established biomarkers to further improve molecular subtyping, this study aims to evaluate the prognostic value of ARID1A in endometrial cancers of NSMP subtype. METHODS: Prospectively collected molecular profiling data of all consecutive patients with endometrial cancer who underwent primary surgery at our department between August 2017 and June 2022 and for whom both molecular profiling and clinical follow-up data were available were retrospectively evaluated...
March 19, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38508521/expanding-the-spectrum-of-nr4a3-fusion-positive-gynecologic-leiomyosarcomas
#32
JOURNAL ARTICLE
Amir Momeni-Boroujeni, Kerry Mullaney, Sara E DiNapoli, Mario M Leitao, Martee L Hensley, Nora Katabi, Douglas H R Allison, Kay J Park, Cristina R Antonescu, Sarah Chiang
Recurrent gene fusions have been observed in epithelioid and myxoid variants of uterine leiomyosarcoma. PGR::NR4A3 fusion was recently described in a subset of epithelioid leiomyosarcomas exhibiting rhabdoid morphology. In this study, we sought to expand the clinical, morphologic, immunohistochemical, and genetic features of gynecologic leiomyosarcomas harboring NR4A3 rearrangement with PGR and novel fusion partners. We identified 9 gynecologic leiomyosarcomas harboring PGR::NR4A3, CARMN::NR4A3, ACTB::NR4A3, and possible SLCO5A1::NR4A3 fusions by targeted RNA sequencing...
March 18, 2024: Modern Pathology
https://read.qxmd.com/read/38507090/ovarian-cancer-management-in-an-esgo-ovarian-cancer-center-of-excellence-a-systematic-case-study-of-the-interprofessional-and-interdisciplinary-interaction
#33
JOURNAL ARTICLE
David J Krankenberg, Mustafa Zelal Muallem, Klaus Pietzner, Radoslav Chekerov, Robert Armbrust, Carmen Beteta, Wenzel Schöning, Marlene Lee, Julia Klews, Jalid Sehouli
PURPOSE: With growing knowledge about ovarian cancer over the last decades, diagnosis, evaluation and treatment of ovarian cancer patients have become highly specialized, and an individually adapted approach should be made in each woman by interdisciplinary cooperation. The present study aims to show the variety and extent of medical specialties involved at our institution according to the European Society of Gynecologic Oncology (ESGO) Quality indicators (QI). METHODS: A woman, diagnosed with high-grade ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) class IVb was selected for a single case observational study...
March 20, 2024: Archives of Gynecology and Obstetrics
https://read.qxmd.com/read/38505595/applications-of-fapi-pet-ct-in-the-diagnosis-and-treatment-of-breast-and-the-most-common-gynecologic-malignancies-a-literature-review
#34
REVIEW
Tengfei Li, Jintao Zhang, Yuanzhuo Yan, Min Tan, Yue Chen
The fibroblast activating protein (FAP) is expressed by some fibroblasts found in healthy tissues. However, FAP is overexpressed in more than 90% of epithelial tumors, including breast and gynecological tumors. As a result, the FAP ligand could be used as a target for diagnosis and treatment purposes. Positron emission tomography/computed tomography (PET/CT) is a hybrid imaging technique commonly used to locate and assess the tumor's molecular and metabolic functions. PET imaging involves the injection of a radiotracer that tends to accumulate more in metabolically active lesions such as cancer...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38504984/tyrosine-phosphatase-ptpn11-shp2-in-solid-tumors-bull-s-eye-for-targeted-therapy
#35
REVIEW
Xun Chen, Steffen Johannes Keller, Philipp Hafner, Asma Y Alrawashdeh, Thomas Yul Avery, Johana Norona, Jinxue Zhou, Dietrich Alexander Ruess
Encoded by PTPN11 , the Src-homology 2 domain-containing phosphatase 2 (SHP2) integrates signals from various membrane-bound receptors such as receptor tyrosine kinases (RTKs), cytokine and integrin receptors and thereby promotes cell survival and proliferation. Activating mutations in the PTPN11 gene may trigger signaling pathways leading to the development of hematological malignancies, but are rarely found in solid tumors. Yet, aberrant SHP2 expression or activation has implications in the development, progression and metastasis of many solid tumor entities...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38501593/a-novel-epc1-kdm2b-fusion-in-high-grade-endometrial-stromal-sarcoma
#36
JOURNAL ARTICLE
Katherine M Vroobel, Sana Khalid, Silvia Cavalchini, Ayoma D Attygalle
The spectrum of endometrial stromal sarcoma (ESS) has expanded substantially since the publication of the most recent World Health Organisation (WHO) Classification of Female Genital Tumours and the advent of widely available genomic testing. We describe a uterine mesenchymal tumor harboring a novel EPC1::KDM2B fusion, best classified within the umbrella of high-grade endometrial stromal sarcoma (HGESS). This tumor was composed of a uniform population of spindled cells with some myxoid stroma, a mitotic rate of up to 21/10 high-power fields, and a largely pushing margin with focal vascular invasion...
March 11, 2024: International Journal of Gynecological Pathology
https://read.qxmd.com/read/38501053/immune-related-adverse-event-related-adrenal-insufficiency-mediates-immune-checkpoint-inhibitors-efficacy-in-cancer-treatment
#37
JOURNAL ARTICLE
Shasha Zhang, Jianhua Wu, Yue Zhao, Jingjing Zhang, Xiaoyun Zhang, Chensi Wu, Zhidong Zhang, Zhanjun Guo
PURPOSE: Immune checkpoint inhibitors (ICIs) have significantly improved the outcomes of patients with cancer; however, these agents may initiate immune-related adverse events (irAEs). Previous studies have demonstrated a robust correlation between disease prognosis and the occurrence of irAEs, specifically skin or endocrine irAEs. Herein, we aimed to evaluate the correlation between irAE-related adrenal insufficiency (AI) and ICI treatment efficacy. PATIENTS AND METHODS: Patients diagnosed with gastrointestinal, respiratory, head and neck, urological, skin and gynecologic cancers treated with anti-programmed cell death 1 (PD-1)/anti-programmed cell death ligand 1 (PD-L1) antibody as monotherapy or combined therapy (combined with chemotherapy or targeted therapy) were divided into irAE-A (patients with irAE-related AI), irAE-B (patients with other irAEs) and non-irAE groups...
2024: Cancer Management and Research
https://read.qxmd.com/read/38500744/case-report-diagnosis-and-treatment-of-advanced-high-grade-serous-ovarian-carcinoma-aided-by-68-ga-fapi-pet-mr-scan
#38
Mengna Zhu, Si Sun, Lin Huang, Mengqing Chen, Jing Cai, Zehua Wang, Liqiong Cai
High-grade serous ovarian cancer (HGSOC) is the most common type of epithelial ovarian cancer with insidious onset, rapid growth, and invasive spread. Here, we reported the diagnosis and treatment of a 53-year-old patient with a history of hysterectomy aided by the 68 Ga-FAPI PET/MR scan. The patient was first presented to the local hospital with a lump on the left side of the neck with a biopsy suggesting metastatic cancer. Pelvic ultrasonography revealed two irregular masses. After admission, tumor markers, pathology consultation of the biopsy, and the 68 Ga-FAPI PET/MR scan were administered...
2024: American Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/38497886/5-signature-genes-revealed-by-single-cell-profiling-identified-unique-immune-subtypes-affecting-the-prognosis-of-ovarian-cancer
#39
JOURNAL ARTICLE
S-Y Xiang, Q-K Li, Z Yang, Q Yi
OBJECTIVE: Ovarian cancer (OC) ranks among the most prevalent gynecological malignancies, with surgery, chemotherapy, and immunotherapy constituting primary treatment modalities. However, despite advancements, immunotherapy, particularly immune checkpoint inhibitors, has yielded suboptimal outcomes. The pressing need to identify biomarkers predictive of clinical prognosis underscores our objective. We aim to discern gene signatures and establish prognostic subgroups, specifically in the context of immunotherapy and chemotherapy, guiding clinical decision-making...
March 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38494510/reproductive-outcomes-in-women-opting-for-fertility-preservation-after-fertility-sparing-surgery-for-borderline-ovarian-tumors
#40
JOURNAL ARTICLE
S Cosyns, E Van Moer, I De Quick, H Tournaye, M De Vos
PURPOSE: What are the reproductive outcomes of women who had fertility preservation (FP) using either oocyte or embryo vitrification after fertility-sparing surgery (FSS) for a borderline ovarian tumor (BOT)? METHODS: A retrospective, single-center cohort study was conducted between January 2013 and December 2021. Patients with BOT who resorted to FP by vitrifying oocytes or embryos were included. Both clinical and reproductive parameters were reviewed. The primary outcome was live birth...
March 17, 2024: Archives of Gynecology and Obstetrics
keyword
keyword
54797
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.